We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca (AZ) has reached an agreement with China’s Kangtai Biologics to help develop and manufacture its promising coronavirus candidate AZD1222, the first deal the British drugmaker has forged for its experimental vaccine in China. Read More
The NIH’s National Institutes of Allergy and Infectious Diseases (NIAID) has launched a phase 3 trial of Gilead Sciences’ remdesivir with Merck’s anti-inflammatory drug Rebif (interferon-beta-1a) for the treatment of hospitalized COVID-19 patients. Read More
As concerns mount over the FDA coming under undue pressure to approve a COVID-19 vaccine, FDA Commissioner Stephen Hahn said again yesterday that the agency won’t take any shortcuts. Read More
In a move that’s likely to shake up the entire U.S. drug supply chain, President Trump signed an executive order yesterday directing the federal government to buy “essential drugs” from domestic companies. Read More
The FDA released guidance for sponsors of drugs for treatment of life-threatening ailments seeking approval under the agency’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) program. Read More
Almost three dozen state attorneys general have called on the federal government to bypass Gilead Sciences’ remdesivir patents and begin producing the COVID-19 treatment. Read More
Massachusetts-based Partner Therapeutics has secured a $35 million contract from the Department of Defense for clinical trials of inhaled Leukine (sargramostim) for the treatment of COVID-19 patients with acute hypoxemia. Read More
Moderna is offering its COVID-19 vaccine candidate at $32 to $37 per dose for smaller-scale supply agreements, the company’s CEO Stéphane Bancel said Wednesday. Read More